Naloxone intranasal - Amphastar

Drug Profile

Naloxone intranasal - Amphastar

Latest Information Update: 28 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amphastar Pharmaceuticals
  • Class Antidotes; Benzofurans; Drug withdrawal therapies; Isoquinolines; Morphinans; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Opioid abuse

Most Recent Events

  • 21 Feb 2017 Amphastar Pharmaceuticals receives complete response letter from the FDA for Naloxone intranasal in Opioid abuse
  • 19 May 2016 Chemical structure information added
  • 01 Apr 2016 Preregistration for Opioid abuse in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top